Ratings by William Blair (Matt Phipps)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/15/2024 | Cullinan Oncology Inc. | CGEM | New Coverage | Outperform (N/A) |
17.37 (16.67) |
-4.03% | Details | |
| 10/27/2023 | Bristol-Myers Squibb Co. | BMY | Downgrade | Market Perform (Outperform) |
52.97 (48.99) |
-7.51% | Details | |
| 6/12/2023 | Chinook Therapeutics | KDNY | Downgrade | Market Perform (Outperform) |
23.99 (40.39) |
68.36% | Details | |
| 3/16/2023 | Kezer Life Sciences | KZR | Downgrade | Market Perform (Outperform) |
4.61 (0.83) |
-82% | Details | |
| 11/14/2022 | Genmab A/S | GMAB | New Coverage | Market Perform (N/A) |
41.84 (28.56) |
-31.74% | Details | |
| 9/28/2022 | PhaseBio Pharmaceuticals Inc. | PHAS | Downgrade | Market Perform (Outperform) |
0.78 (0.07) |
-91.03% | Details | |
| 6/23/2022 | F-Star Therapeutics Inc. | FSTX | Downgrade | Market Perform (Outperform) |
3.98 (7.12) |
78.89% | Details | |
| 11/9/2021 | MiNK Therapeutics | INKT | New Coverage | Outperform (N/A) |
18.96 (0.87) |
-95.41% | Details | |
| 11/5/2021 | Calithera Biosciences | CALA | Downgrade | Market Perform (Outperform) |
1.90 (0.37) |
-80.53% | Details | |
| 10/21/2021 | Jasper Therapeutics | JSPR | New Coverage | Outperform (N/A) |
14.20 (22.11) |
55.7% | Details | |
| 10/21/2021 | Tempest Therapeutics | TPST | New Coverage | Outperform (N/A) |
13.90 (3.42) |
-75.4% | Details | |
| 6/8/2021 | Biogen | BIIB | Upgrade | Outperform (Market Perform) |
395.85 (193.18) |
-51.2% | Details | |
| 4/8/2021 | F-Star Therapeutics Inc. | FSTX | New Coverage | Outperform (N/A) |
10.20 (7.12) |
-30.2% | Details | |
| 4/8/2021 | Merus N.V. | MRUS | New Coverage | Outperform (N/A) |
22.28 (40.82) |
83.21% | Details | |
| 11/9/2020 | Codiak Biosciences Inc. | CDAK | New Coverage | Outperform (N/A) |
9.09 (0.06) |
-99.34% | Details | |
| 7/21/2020 | Dynavax Technologies | DVAX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2020 | Portola Pharmaceuticals | PTLA | Downgrade | Market Perform (Outperform) |
7.76 (18.03) |
132.35% | Details | |
| 12/18/2019 | Aduro Biotech | ADRO | Downgrade | Market Perform (Outperform) |
1.15 (14.60) |
1169.57% | Details | |
| 9/16/2019 | Atara Biotherapeutics | ATRA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/11/2019 | PhaseBio Pharmaceuticals Inc. | PHAS | New Coverage | Outperform (N/A) |
5.20 (0.07) |
-98.65% | Details | |
| 7/16/2019 | Atara Biotherapeutics | ATRA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/21/2019 | Biogen | BIIB | Downgrade | Market Perform (Outperform) |
320.59 (395.85) |
23.48% | Details |
